Vaccines for covid-19 patients

As part of the COVID-NMA initiative, we are identifying all randomized controlled trials (RCTs) of COVID-19 vaccine.

Below, you can access

Of note: For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.

We present the risk of Bias for phase 1-2 studies assessed for safety outcomes only.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison:

Press releases

We acknowledged the publication of press release on the findings of the Novavax vaccine: COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial ">Novavax vaccine We will summarize and assess the study results once the full study reports have been published.

Last update: 16/04/2021

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04470427
ModernaTX
Baden LR, N Engl J Med, 2020
COVE
New

Full text
Full text
; Full text
Full text
Commentary
RNA based vaccine

mRNA-1273

Placebo

RCT
Phase 3
Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US N=30420
Some concerns
Details

Full description

NCT04368728
BioNTech/Fosun Pharma/Pfizer
Polack F, N Engl J Med, 2020

Full text
Commentary
; Commentary
; Commentary
; Commentary
; Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2/3
Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA N=43448
Some concerns
Details

Full description

NCT04368728
BioNTech SE, Pfizer
Walsh E, N Engl J Med, 2020
New

Full text
Commentary
RNA based vaccine

BNT162b1 10 mcg D1/21

BNT162b1 20 mcg D1/21

BNT162b1 30 mcg D1/21

BNT162b1 100 mcg D1/21

BNT162b2 10 mcg D1/21

BNT162b2 20 mcg D1/21

BNT162b2 30 mcg D1/21

BNT162b1 30 mcg D1/21

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA N=195
Low
Details

Full description

The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.

The risk of bias by domain as well as overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.